- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.12. | XOMA Preferred Shares Series A declares $0.5391 dividend | 2 | Seeking Alpha | ||
| 19.12. | XOMA Corp - 8.375% DP PFD B declares $0.5234 dividend | 1 | Seeking Alpha | ||
| XOMA CORPORATION PREF Aktie jetzt für 0€ handeln | |||||
| 19.12. | XOMA Royalty Corporation: XOMA Royalty Declares Quarterly Preferred Stock Dividends | 1 | GlobeNewswire (USA) | ||
| 10.12. | XOMA AB: First Delivery of Process Water from a Swedish Industry | 1 | Cision News | ||
| 06.12. | XOMA AB: Xoma engages Kalqyl and FairValue to strengthen its investor communications | 2 | Cision News | ||
| 03.12. | A Glimpse Into The Expert Outlook On XOMA Royalty Through 4 Analysts | 2 | Benzinga.com | ||
| 02.12. | XOMA Royalty Owns Economic Interest In Seralutinib With Pulmokine Purchase; Stock Up | 1 | RTTNews | ||
| 02.12. | XOMA Royalty Corp - 8-K, Current Report | - | SEC Filings | ||
| 02.12. | XOMA Corporation: XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio | 98 | GlobeNewswire (Europe) | Seralutinib becomes XOMA Royalty's seventh Phase 3 royalty asset, further building the late-stage pipeline beyond its six current commercial royalty assets Seralutinib is being developed and co-commercialized... ► Artikel lesen | |
| 26.11. | XOMA-Aktie erreicht 52-Wochen-Hoch bei 34 US-Dollar | 2 | Investing.com Deutsch | ||
| 26.11. | XOMA Stock Soars to 52-Week High, Reaching $34 Amidst Strong Growth | 1 | Investing.com | ||
| 19.11. | Spotlight Stock Market: Market Notice 237/24 - Xoma AB will be listed on Spotlight Stock Market on November 22, 2024 | 3 | Cision News | ||
| 07.11. | XOMA Corporation: XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities | 106 | GlobeNewswire (Europe) | Zevra's MIPLYFFA (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty's portfolio XOMA Royalty acquired a 50 percent economic interest in TWIST Bioscience's portfolio... ► Artikel lesen | |
| 07.11. | XOMA Royalty Corp - 8-K, Current Report | - | SEC Filings | ||
| 07.11. | XOMA Royalty Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 29.10. | XOMA stock soars to 52-week high, reaching $30.7 | 1 | Investing.com | ||
| 29.10. | XOMA-Aktie erreicht 52-Wochen-Hoch bei 30,7 US-Dollar | 3 | Investing.com Deutsch | ||
| 22.10. | Twist Bioscience enters into purchase agreement with XOMA Royalty | 10 | Seeking Alpha | ||
| 22.10. | XOMA Royalty Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 22.10. | XOMA Corporation: XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience | 3 | GlobeNewswire (USA) |
Seite:
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|
XOMA CORPORATION PREF gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 24,600 Euro und damit +0,82 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XOMA CORPORATION PREF finden Sie auf Wallstreet Online.
